Stay updated on Letetresgene Autoleucel+Pembrolizumab in NY-ESO-1+ MM Clinical Trial
Sign up to get notified when there's something new on the Letetresgene Autoleucel+Pembrolizumab in NY-ESO-1+ MM Clinical Trial page.

Latest updates to the Letetresgene Autoleucel+Pembrolizumab in NY-ESO-1+ MM Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoNo Change Detected
- Check18 days agoChange DetectedThe page now displays Revision: v3.5.4, replacing the prior v3.5.3 tag. This indicates a minor page version update rather than any change to the study data.SummaryDifference0.0%

- Check25 days agoNo Change Detected
- Check32 days agoChange DetectedThe page shows a new revision label. It updates from Revision: v3.5.2 to Revision: v3.5.3, signaling a software release rather than substantive changes to the study data or content.SummaryDifference0.0%

- Check47 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2. No user-facing content or layout changes are evident.SummaryDifference0.0%

- Check75 days agoChange DetectedRevision: v3.5.0 was added and v3.4.3 was removed.SummaryDifference0.0%

- Check82 days agoChange DetectedA backend version update shows revision v3.4.3 replacing v3.4.2. No visible changes to study content or user-facing features.SummaryDifference0.0%

- Check111 days agoChange DetectedRevision: v3.4.2 is now shown on the page. Notices about government funding lapse and an older Revision: v3.4.1 have been removed.SummaryDifference0.4%

Stay in the know with updates to Letetresgene Autoleucel+Pembrolizumab in NY-ESO-1+ MM Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Letetresgene Autoleucel+Pembrolizumab in NY-ESO-1+ MM Clinical Trial page.